Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cancer biomarker that are currently used in cancer therapy and under evaluation in clinical trials.

Advances in cancer research - 1 Jan 2026

Tyagi Lakshita, Mishra Shreeja, Simran, Singh Harjinder, Kumar Manoj, Rathi Garima, Kaur Navneet, Sehgal Satbir Singh, Kumar Umesh

Abstract excerpt

Cancer biomarkers significantly advance precision oncology by giving physicians guidance about treatment options based on the molecular characteristics of a person's tumor, allowing for personalized cancer care. When used collectively, the identification of these cancer biomarkers will lead to better selection of appropriate therapies, facilitate monitoring of response to treatment, and provide rapid evaluation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to PIK3CA gene

Share to Molecular Targeted Therapy

Share to Mutation

Share to Neoplasms

Share to Precision Medicine

Share to Proto-Oncogene Mas

Source

Identifiers

PMID: 42167845
DOI: 10.1016/bs.acr.2025.12.010

Genes

BRAF
EGFR
ESR1
PIK3CA

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cancer biomarker that are currently used in cancer therapy and under evaluation in clinical trials.PMID 42167845Read ↗

INTERESTing biomarker to select IDEAL patients for epidermal growth factor receptor tyrosine kinase inhibitors: yes, for EGFR mutation analysis, others, I PASS.Semantic proximity Read ↗

Emerging technologies for improved stratification of cancer patients: a review of opportunities, challenges, and tools.Semantic proximity Read ↗

Critical comments for roles of biomarkers in the diagnosis and treatment of cancer.Semantic proximity Read ↗

Exploitation of Gene Expression and Cancer Biomarkers in Paving the Path to Era of Personalized MedicineSemantic proximity Read ↗

Considerations About the Use of Biomarkers in Cancer Clinical Trials.Semantic proximity Read ↗

Cancer molecular markers: A guide to cancer detection and management.Semantic proximity Read ↗

Companion biomarkers: paving the pathway to personalized treatment for cancer.Semantic proximity Read ↗

Biomarker update for breast, colorectal and non-small cell lung cancer.Semantic proximity Read ↗

Personalized medicine using DNA biomarkers: a reviewSemantic proximity Read ↗

NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology.Semantic proximity Read ↗

Pan-Cancer Biomarkers: Changing the Landscape of Molecular Testing.Semantic proximity Read ↗

Molecular biomarkers for cancer detection in blood and bodily fluids.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.